Dave Chawla, MD
Cardiovascular Disease · Marble Falls, TXNPI 1275790149
Payments from drug & device makers
Across 20 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$92
- Heartflow, Inc.$76
- Esperion Therapeutics, Inc.$42
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
- AstraZeneca$34
- Boston Scientific$26
- plus $90 from 5 others
What the payments were for
- Food & beverage$395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $92 |
| Heartflow, Inc. | 2 | $76 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| AstraZeneca | 2 | $34 |
| Boston Scientific | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
How this compares
$395 in reported general payments places this provider in the 15th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 185 | $226,587 |
| Repatha SureclickEvolocumab | 123 | $140,615 |
| XareltoRivaroxaban | 52 | $61,603 |
| Praluent PenAlirocumab | 61 | $52,062 |
| MultaqDronedarone Hcl | 27 | $30,348 |
| Repatha SyringeEvolocumab | 16 | $16,236 |
| Ezetimibe | 263 | $7,858 |
| Metoprolol Succinate | 238 | $4,440 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 102 | $3,391 |
| Candesartan Cilexetil | 33 | $3,176 |
| Bisoprolol Fumarate | 113 | $3,100 |
| Potassium Chloride | 105 | $2,573 |
| Losartan Potassium | 200 | $2,570 |
| Rosuvastatin Calcium | 223 | $2,501 |
| Atorvastatin Calcium | 245 | $2,493 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Marble Falls
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.